Clinical Trials Logo

Filter by:
NCT ID: NCT04431128 Completed - Adenoid Hypertrophy Clinical Trials

Adenoid Hypertrophy, Respiratory Complications and Correlation With Infant Feeding Position

Start date: January 1, 2003
Phase:
Study type: Observational

500 children aged 0-5 years followed since birth by Principal Investigator (PI)since January1, 2003 till December 31, 2018 and diagnosed with adenoid hypertrophy (AH) (study group) and 500 children aged 0-5 years followed by principal investigator during the same years and diagnosed as urinary tract infection (UTI), gastroenteritis (GE), diarrhea, vomiting but without AH (control group) were compared. Morbidity and treatment will be compared and correlated with gastro-esophageal reflux (GER), allergy and infant feeding position during the first few years of life in the two groups.

NCT ID: NCT04419467 Completed - Clinical trials for Diabetic Kidney Disease (DKD)

Vascular Endothelial Growth Factor-B (VEGF-B) Blockade With the Monoclonal Antibody CSL346 in Subjects With Diabetic Kidney Disease

Start date: September 14, 2020
Phase: Phase 2
Study type: Interventional

This phase 2a, double-blind, randomized, placebo-controlled study will assess the efficacy, safety, tolerability, and pharmacokinetics (PK), of repeat doses of CSL346 in subjects with diabetic kidney disease (DKD) and albuminuria receiving standard of care treatment.

NCT ID: NCT04414774 Completed - Suicide Ideation Clinical Trials

Assessing the Effectiveness of a CBT-based App in Reducing Suicidal Ideation

Start date: June 14, 2020
Phase: N/A
Study type: Interventional

The aim of this study is to empirically assess the utility of GG-Suicide-Ideation (GGSI), a theory-based mobile application for the prevention of suicide ideation. GGSI is based on principles of Cognitive Behavioral Therapy (CBT), which have been found to be an effective treatment for decreasing suicide risk. In this study half of the participants (i.e. the experiment group) will start an immediate use of GGSI for a period of 15 days. The other half of the participants (i.e. the control group) will be 'on hold' during the first 15 days, after which they will commence use of GGSI for an additional 15 days. All participants will complete questionnaires regarding suicide ideation and related risk factors three times during the study: at the beginning of the study (baseline), after 15 days from the beginning of study and after 30 days from the beginning of study. The investigators hypothesized that in the experimental group, after 15 days of using GGSI app there will be a substantial decrease in the level of suicide ideation and associate risk factors, compared to the control group. If this hypothesis is met, the investigators will examine if the decrease in said measures in the experimental group will maintain after 15 days of follow up. In addition, the investigators hypothesized that in the control group there will be a significant decrease in suicide ideation and related risk factors after 15 days of using GGSI.

NCT ID: NCT04414618 Completed - Clinical trials for Coronavirus Infections

A Study of Opaganib in Coronavirus Disease 2019 Pneumonia

COVID-19
Start date: July 2, 2020
Phase: Phase 2
Study type: Interventional

This proof of concept study will take place in the US and other countries in approximately 15 clinical sites and will enroll about 40 hospitalized patients diagnosed with COVID-19 infection who have developed pneumonia and require supplemental oxygen. 20 patients will receive opaganib in addition to standard of care twice each day for 14 days. 20 will receive matching placebo in addition to standard of care unless the patient has been discharged from the hospital without requiring supplemental oxygen, in which case study drug will only be administered for 10 days. All participants will be followed up for 4 weeks after their last dose of study drug.

NCT ID: NCT04414085 Completed - Retrospective Clinical Trials

The Clinical Significance of Biochemical 11 Deoxycortisol Levels

Start date: October 15, 2015
Phase:
Study type: Observational

data from charts regarding clinical characteristics and androgens levels from first to last visit were collected

NCT ID: NCT04414033 Completed - Breast Cancer Clinical Trials

Bubble: A New VR-AI Way of Treatment for Hot Flashes in Women With Breast Cancer

Start date: February 1, 2018
Phase: N/A
Study type: Interventional

This study evaluates the potential of a unique artificial intelligence-virtual reality intervention called Bubble, to reduce the number and intensity of hot flashes and their accompanying psychological symptoms in women, aged 28-55, with breast cancer. A sample of 37 women with breast cancer were selected to the study. Participants were asked to answer a survey before and after using Bubble. The treatment period was 24 days. The findings are positive and show that the use of Bubble help to reduce several psychological symptoms connected to hot flashes.

NCT ID: NCT04406402 Completed - Obesity Clinical Trials

L-arginine and Asymmetric Dimethylarginine (ADMA) and Lifestyle Protocols

Start date: December 5, 2006
Phase: N/A
Study type: Interventional

Low serum L-arginine (Arg) and high asymmetric dimethylarginine (ADMA) can predict microvascular complications in type 2 diabetes (T2DM). The investigators examined whether or not Arg and ADMA are affected by dietary factors or lifestyle modification in overweight/ obese and T2DM subjects.

NCT ID: NCT04406142 Completed - Clinical trials for Respiratory Distress Syndrome, Newborn

Surfactant Administration Via Thin Catheter Using a Specially Adapted Video Laryngoscope - the VISUAL Method

VISUAL
Start date: July 15, 2018
Phase: N/A
Study type: Interventional

Surfactant administration via thin catheter using a specially adapted video laryngoscope - a prospective, multicenter trial, assessing the feasibility of the VISUAL method (Video Surfactant Administration Laryngoscopy). The study will search for the number of attempts until surfactant is administrated, assessment of the infants' stability during the procedure, duration of the entire procedure, form laryngoscope insertion to surfactant administration.

NCT ID: NCT04406077 Completed - Hydrocele Clinical Trials

The Use of Ligasure (r) for Hydrocelectomy Surgery

Start date: February 18, 2018
Phase: N/A
Study type: Interventional

Hydrocele is a condition of fluid retention around the testes, which causes swallowing, pain, with interfering with the normal testes function. however, during activity, this can interfere with everyday activity (running, sexual intercourse). The treatment for hydrocele I surgical. The study aim to test the safety and efficacy of the Ligasure (r) device for cutting and coagulating tissues during hydrocelectomy.

NCT ID: NCT04399408 Completed - Clinical trials for Ultrasonography, Prenatal

Instinctâ„¢ Ultrasound Device Safety, Efficacy and Usability

Start date: May 6, 2019
Phase: N/A
Study type: Interventional

Mobile medical devices for self-patient-use, are a rapidly evolving component of telehealth. Study examines the feasibility of using the INSTINCT® device, a portable self-use ultrasound system attached to a commercial smartphone in remote pregnancy assessment. Study aims to evaluate its safety, efficacy and usability.